Developer docs
API playgroundTry for free, no card

Search company profiles

Astrogen, inc.

Full company profile

uuid0002hft

Namestring
Astrogen, inc.
Legal namestring
(주)아스트로젠
Websiteurl
astrogen.co.kr
Company typeenum
Private
Founded yearint
2017
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersDaegu, South Korea
HQ citystring
Daegu
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neurological drug development, autism spectrum disorder treatment, CNS pharmaceutical pipeline, small molecule therapeutics, orphan drug designation
Industry1 code
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
CNS Pharmaceutical Development
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Product Supply Revenue
TypeOne Time License
Description

Direct revenue from supplying AST-001 (Speragen) drug product. The Middle East deal includes $131 million for product supply with an additional $77.5 million upon Korean regulatory approval, plus double-digit royalties on future sales.

koreajoongangdaily.joins.com
2Technology Transfer and Licensing
TypeLicensing Royalties
Description

Revenue from technology transfer deals including the $208.5 million deal with Cigalah Medpharm for exclusive commercialization rights in 16 MENA countries. Includes milestone payments and ongoing royalties.

en.yna.co.kr
3Royalty Income
TypeLicensing Royalties
Description

Double-digit royalties on future product sales in Middle East markets through the Cigalah Medpharm partnership.

koreajoongangdaily.joins.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1스텔라 스텝스 (Stellar Steps)
Description

A self-help and independence education program for adolescents with autism and developmental disabilities, operated as part of Astrogen's ESG social contribution activities.

astrogen.co.kr
+1 more record
Core offering1 text field

Astrogen, Inc. is a clinical-stage pharmaceutical company developing small-molecule therapies for neurological and rare diseases. Its lead candidate Speragen (AST-001) is an oral syrup for autism spectrum disorder (ASD) targeting core social communication symptoms via SK channel regulation and dopamine signaling normalization. The pipeline also addresses Alzheimer's, Parkinson's, stroke, traumatic brain injury, and glioblastoma.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Social adaptability improved in 61% at 12 weeks and 78% at 24 weeks in high-dose group based on Vineland Adaptive Behavior Composite scores
+4 more records
Product overview1 text field

Astrogen is a clinical-stage pharmaceutical company developing treatments for intractable neurological disorders. Its core product is Speragen (AST-001), an oral syrup for autism spectrum disorder core symptoms, which completed Phase 3 trials with NDA submitted in Korea in June 2025 and a $208.5M technology transfer deal signed for 16 MENA countries. The pipeline spans multiple neurological indications: AST-002 (traumatic brain injury, Phase 1 pending), AST-011 (Alzheimer’s, preclinical with K-Medihub), AST-029 (Parkinson’s, AI-designed with IKTOS, preclinical), AST-009 (Parkinson’s, peptide, preclinical), AST-025 (stroke, preclinical), AST-003 (ASD for global transfer, preclinical), and AST-035A (anticancer, molecular glue for glioblastoma, preclinical). The company also operates Stellar Steps, a social program providing free ADL training for adolescents with developmental disabilities.

Product and service8 records
1Speragen (AST-001)
CategoryCore Pharmaceutical Product
Description

Oral syrup drug candidate for treating core symptoms of autism spectrum disorder (ASD) in children ages 2 and older. Targets social communication deficits and restricted/repetitive behaviors via synaptic pruning activation and dopamine signal normalization through SK channel regulation. NDA submitted to Korean MFDS in June 2025.

2AST-002
CategoryPipeline Pharmaceutical Product
Description

Injectable drug candidate for traumatic brain injury and cerebrovascular disease treatment. Reformulated existing drug with new indication, with Phase 1 IND application under preparation.

3AST-011 (Alzheimer's disease treatment)
CategoryPipeline Pharmaceutical Product
Description

Low-molecule compound for Alzheimer's disease treatment, currently in preclinical stage. Jointly developed with K-Medihub and targeting clinical Phase 1 entry.

4AST-029 (Parkinson's disease treatment)
CategoryPipeline Pharmaceutical Product
Description

Parkinson's disease drug candidate targeting a specific mutated gene variant. Developed in collaboration with France-based IKTOS using AI-driven compound design. Currently in preclinical stage.

5AST-009 (Parkinson's disease treatment)
CategoryPipeline Pharmaceutical Product
Description

Peptide compound for Parkinson's disease treatment, in candidate substance identification stage. Part of the broader Parkinson's pipeline alongside AST-029.

6AST-025 (Stroke treatment)
CategoryPipeline Pharmaceutical Product
Description

Innovative new drug candidate for stroke treatment, currently in candidate substance derivation stage.

7AST-003 (ASD treatment, global target)
CategoryPipeline Pharmaceutical Product
Description

Autism spectrum disorder treatment candidate in preclinical stage, positioned for global technology transfer (not self-clinical development).

8AST-035A (Glioblastoma treatment)
CategoryPipeline Pharmaceutical Product
Description

Next-generation anticancer drug candidate based on molecular glue technology, targeting glioblastoma as primary indication with potential expansion to liver cancer and other treatment-resistant cancers. In preclinical stage with IND preparation underway in collaboration with DTCRO.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-01-07
Description

Exclusive technology transfer and commercialization partnership for Speragen (AST-001) covering 16 countries in Middle East and North Africa. Deal valued at $208.5 million including $131M product supply, $77.5M upon Korean regulatory approval, plus double-digit royalties on future sales. Cigalah is the largest healthcare distribution group in MENA region with #1 market position in Saudi Arabia SFDA registered products.

2Honeyist
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-10-23
Description

Joint development of customized oral care products for children with ASD. 'Bubble Gargle' product being developed for children with sensory sensitivity who struggle with toothbrushing. Astrogen provides clinical research data and medical insights; Honeyist provides formulation development and safety testing.

astrogen.co.kr
3Korean Society of Pediatric and Adolescent Behavioral Development (대한소아청소년 행동발달증진학회)
Strategic tierMinorTypeOthersAnnounced on2025-09-30
Description

MOU for improving treatment systems for developmental disorders, strengthening medical professional education, social awareness promotion, and policy recommendations. Society committed to supporting Speragen market adoption upon approval.

astrogen.co.kr
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-01-13
Description

Preclinical and clinical CRO partnership for next-generation anticancer drug candidate AST-035A development. AST-035A uses molecular glue technology targeting glioblastoma. DT&CRO provides clinical trial design and research support for global market entry.

Strategic tierMajorTypeImplementation/ SI/ Consulting PartnerAnnounced on2023-07-25
Description

Strategic partnership for GMP manufacturing of AST-001 Phase 3 clinical trial materials. Nexpharm Korea provides pharmaceutical production facilities meeting global GMP standards. Partnership expanded from Phase 2 collaboration following successful clinical trial completion.

6Kemedihub (대구경북첨단의료산업진흥재단)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-06-21
Description

Multi-faceted partnership including drug development cooperation, GMP production, and digital healthcare device development. Astrogen's lead pipeline AST-001 manufactured at Kemedihub facilities. Joint research on Parkinson's disease and cerebellar atrophy treatments. Also collaborated with NewDive on ASD digital therapeutic development.

astrogen.co.kr
7Agarson Bio
Strategic tierMajorTypeTechnology or IntegrationAnnounced on2023-05-19
Description

API (active pharmaceutical ingredient) supply partnership for AST-001 Phase 3 clinical trials. Agarson Bio supplies raw materials for clinical trial production and will support overseas production capacity for international commercialization.

astrogen.co.kr
8Daegu Fatima Hospital
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-02-01
Description

Healthcare joint research MOU for clinical trial cooperation, health promotion services, and business collaboration. Fatima Medical Research Institute partnership for mutual research system establishment.

astrogen.co.kr
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-01-06
Description

AI-powered drug discovery collaboration for Parkinson's disease treatment. IKTOS provides novel compound design and optimization using active learning-based structure generation modeling. Astrogen handles efficacy verification, preclinical, and clinical development. First Korean partnership for IKTOS in the biopharmaceutical sector.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2020-07-29
Description

Joint development partnership for degenerative brain diseases and nervous system disorders. J2H Biotech provides drug design, synthesis, and CMC capabilities; Astrogen handles efficacy evaluation, formulation development, and clinical strategy. Partnership leverages complementary strengths in CNS drug development.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Curemark
TypeDirect peer
Description

Curemark is a clinical-stage biopharmaceutical company developing CM-AT for the treatment of autism spectrum disorder, making it one of the few direct peers pursuing a pharmacological therapy for pediatric ASD core symptoms.

TypeDirect peer
Description

Yamo Pharmaceuticals is developing L-1-methylfolate for autism spectrum disorder and is a direct competitor in the same target indication (ASD) and patient population.

TypeDirect peer
Description

PaxMedica is a clinical-stage pharmaceutical company developing suramin for neurodevelopmental disorders including autism, with overlapping CNS/rare disease focus and similar pre-commercial stage.

TypeDirect peer
Description

Marinus Pharmaceuticals develops CNS therapeutics for rare seizure disorders and is comparable as a small-cap clinical-to-commercial CNS specialty company with similar regulatory pathway dynamics.

TypeBroad incumbent
Description

Hanmi Pharmaceutical is one of Korea's largest pharmaceutical companies with a significant CNS and rare disease franchise, comparable as a much larger domestic incumbent with overlapping therapeutic categories.

TypeBroad incumbent
Description

BioMarin Pharmaceutical is a global rare disease specialist with established orphan drug commercialization capabilities, comparable in business model and regulatory pathway to Astrogen's Speragen program.

TypeBroad incumbent
Description

Jazz Pharmaceuticals is a specialty CNS pharmaceutical company with rare neurology assets, comparable as an established player that built commercial CNS franchises through licensing and acquisition.

TypeBroad incumbent
Description

Supernus Pharmaceuticals is a specialty CNS company focused on neurology and psychiatry products, comparable as a US-listed CNS-focused specialty pharma with established commercial infrastructure.

TypeRegional player
Description

Yuhan Corporation is one of Korea's largest pharmaceutical companies with CNS and rare disease programs, comparable as a domestic Korean pharmaceutical incumbent and potential commercial partner for Astrogen.

10IKTOS
TypeOthers
Description

IKTOS is a French AI-driven drug discovery company and Astrogen's technology partner for Parkinson's pipeline development, comparable as a collaborator/ecosystem participant rather than direct competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses6 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Astrogen, inc.

CNS Pharmaceutical Developmentastrogen.co.kr

Astrogen, inc. firmographics

Firmographics
Name
Astrogen, inc.
Legal name
(주)아스트로젠
Website
https://astrogen.co.kr
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Astrogen, inc. industry classification

Industry
Product category
CNS Pharmaceutical Development
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Neurological drug development
  • Autism spectrum disorder treatment
  • CNS pharmaceutical pipeline
  • Small molecule therapeutics
  • Orphan drug designation

Where Astrogen, inc. is headquartered

Location

Headquarters

HQ city
Daegu
HQ country
South Korea
HQ region
Asia

Offices4 records

Markets served

Astrogen, inc. business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Product Supply Revenue: Direct revenue from supplying AST-001 (Speragen) drug product. The Middle East deal includes $131 million for product supply with an additional $77.5 million upon Korean regulatory approval, plus double-digit royalties on future sales.
  2. Technology Transfer and Licensing: Revenue from technology transfer deals including the $208.5 million deal with Cigalah Medpharm for exclusive commercialization rights in 16 MENA countries. Includes milestone payments and ongoing royalties.
  3. Royalty Income: Double-digit royalties on future product sales in Middle East markets through the Cigalah Medpharm partnership.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels9 records

Astrogen, inc. product offering

Product offering

Core offering

Astrogen, Inc. is a clinical-stage pharmaceutical company developing small-molecule therapies for neurological and rare diseases. Its lead candidate Speragen (AST-001) is an oral syrup for autism spectrum disorder (ASD) targeting core social communication symptoms via SK channel regulation and dopamine signaling normalization. The pipeline also addresses Alzheimer's, Parkinson's, stroke, traumatic brain injury, and glioblastoma.

Product overview

Astrogen is a clinical-stage pharmaceutical company developing treatments for intractable neurological disorders. Its core product is Speragen (AST-001), an oral syrup for autism spectrum disorder core symptoms, which completed Phase 3 trials with NDA submitted in Korea in June 2025 and a $208.5M technology transfer deal signed for 16 MENA countries. The pipeline spans multiple neurological indications: AST-002 (traumatic brain injury, Phase 1 pending), AST-011 (Alzheimer’s, preclinical with K-Medihub), AST-029 (Parkinson’s, AI-designed with IKTOS, preclinical), AST-009 (Parkinson’s, peptide, preclinical), AST-025 (stroke, preclinical), AST-003 (ASD for global transfer, preclinical), and AST-035A (anticancer, molecular glue for glioblastoma, preclinical). The company also operates Stellar Steps, a social program providing free ADL training for adolescents with developmental disabilities.

Differentiator

Problem solved

Functional benefit

Brands

  • 스텔라 스텝스 (Stellar Steps): A self-help and independence education program for adolescents with autism and developmental disabilities, operated as part of Astrogen's ESG social contribution activities.
  • 스페라젠 (Speragen)

Products and services

  • Speragen (AST-001) Oral syrup drug candidate for treating core symptoms of autism spectrum disorder (ASD) in children ages 2 and older. Targets social communication deficits and restricted/repetitive behaviors via synaptic pruning activation and dopamine signal normalization through SK channel regulation. NDA submitted to Korean MFDS in June 2025.
  • AST-002 Injectable drug candidate for traumatic brain injury and cerebrovascular disease treatment. Reformulated existing drug with new indication, with Phase 1 IND application under preparation.
  • AST-011 (Alzheimer's disease treatment) Low-molecule compound for Alzheimer's disease treatment, currently in preclinical stage. Jointly developed with K-Medihub and targeting clinical Phase 1 entry.
  • AST-029 (Parkinson's disease treatment) Parkinson's disease drug candidate targeting a specific mutated gene variant. Developed in collaboration with France-based IKTOS using AI-driven compound design. Currently in preclinical stage.
  • AST-009 (Parkinson's disease treatment) Peptide compound for Parkinson's disease treatment, in candidate substance identification stage. Part of the broader Parkinson's pipeline alongside AST-029.
  • AST-025 (Stroke treatment) Innovative new drug candidate for stroke treatment, currently in candidate substance derivation stage.
  • AST-003 (ASD treatment, global target) Autism spectrum disorder treatment candidate in preclinical stage, positioned for global technology transfer (not self-clinical development).
  • AST-035A (Glioblastoma treatment) Next-generation anticancer drug candidate based on molecular glue technology, targeting glioblastoma as primary indication with potential expansion to liver cancer and other treatment-resistant cancers. In preclinical stage with IND preparation underway in collaboration with DTCRO.

Quantifiable outcome

  • Social adaptability improved in 61% at 12 weeks and 78% at 24 weeks in high-dose group based on Vineland Adaptive Behavior Composite scores
  • +4 more outcomes

Companies that use Astrogen, inc.

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles1 record

Astrogen, inc. technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability3 records

Feature3 records

Astrogen, inc. partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core, minor and major.

  • Cigalah Medpharm Trading LLCcoreChannel Partner/ Reseller/ Distributor · 7 January 2026Exclusive technology transfer and commercialization partnership for Speragen (AST-001) covering 16 countries in Middle East and North Africa. Deal valued at $208.5 million including $131M product supply, $77.5M upon Korean regulatory approval, plus double-digit royalties on future sales. Cigalah is the largest healthcare distribution group in MENA region with #1 market position in Saudi Arabia SFDA registered products.
  • HoneyistminorStrategic or Co-development Partner · 23 October 2025Joint development of customized oral care products for children with ASD. 'Bubble Gargle' product being developed for children with sensory sensitivity who struggle with toothbrushing. Astrogen provides clinical research data and medical insights; Honeyist provides formulation development and safety testing.
  • Korean Society of Pediatric and Adolescent Behavioral Development (대한소아청소년 행동발달증진학회)minorOthers · 30 September 2025MOU for improving treatment systems for developmental disorders, strengthening medical professional education, social awareness promotion, and policy recommendations. Society committed to supporting Speragen market adoption upon approval.
  • DT&CROminorStrategic or Co-development Partner · 13 January 2025Preclinical and clinical CRO partnership for next-generation anticancer drug candidate AST-035A development. AST-035A uses molecular glue technology targeting glioblastoma. DT&CRO provides clinical trial design and research support for global market entry.
  • Nexpharm KoreamajorImplementation/ SI/ Consulting Partner · 25 July 2023Strategic partnership for GMP manufacturing of AST-001 Phase 3 clinical trial materials. Nexpharm Korea provides pharmaceutical production facilities meeting global GMP standards. Partnership expanded from Phase 2 collaboration following successful clinical trial completion.
  • Kemedihub (대구경북첨단의료산업진흥재단)majorStrategic or Co-development Partner · 21 June 2023Multi-faceted partnership including drug development cooperation, GMP production, and digital healthcare device development. Astrogen's lead pipeline AST-001 manufactured at Kemedihub facilities. Joint research on Parkinson's disease and cerebellar atrophy treatments. Also collaborated with NewDive on ASD digital therapeutic development.
  • Agarson BiomajorTechnology or Integration · 19 May 2023API (active pharmaceutical ingredient) supply partnership for AST-001 Phase 3 clinical trials. Agarson Bio supplies raw materials for clinical trial production and will support overseas production capacity for international commercialization.
  • Daegu Fatima HospitalminorStrategic or Co-development Partner · 1 February 2023Healthcare joint research MOU for clinical trial cooperation, health promotion services, and business collaboration. Fatima Medical Research Institute partnership for mutual research system establishment.
  • IKTOS (France)coreTechnology or Integration · 6 January 2022AI-powered drug discovery collaboration for Parkinson's disease treatment. IKTOS provides novel compound design and optimization using active learning-based structure generation modeling. Astrogen handles efficacy verification, preclinical, and clinical development. First Korean partnership for IKTOS in the biopharmaceutical sector.
  • J2H BiotechmajorStrategic or Co-development Partner · 29 July 2020Joint development partnership for degenerative brain diseases and nervous system disorders. J2H Biotech provides drug design, synthesis, and CMC capabilities; Astrogen handles efficacy evaluation, formulation development, and clinical strategy. Partnership leverages complementary strengths in CNS drug development.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Astrogen, inc. competitors and assessment

Company assessment

Direct peers

  • Curemark: Curemark is a clinical-stage biopharmaceutical company developing CM-AT for the treatment of autism spectrum disorder, making it one of the few direct peers pursuing a pharmacological therapy for pediatric ASD core symptoms.
  • Yamo Pharmaceuticals: Yamo Pharmaceuticals is developing L-1-methylfolate for autism spectrum disorder and is a direct competitor in the same target indication (ASD) and patient population.
  • PaxMedica: PaxMedica is a clinical-stage pharmaceutical company developing suramin for neurodevelopmental disorders including autism, with overlapping CNS/rare disease focus and similar pre-commercial stage.
  • Marinus Pharmaceuticals: Marinus Pharmaceuticals develops CNS therapeutics for rare seizure disorders and is comparable as a small-cap clinical-to-commercial CNS specialty company with similar regulatory pathway dynamics.

Broad incumbents

  • Hanmi Pharmaceutical: Hanmi Pharmaceutical is one of Korea's largest pharmaceutical companies with a significant CNS and rare disease franchise, comparable as a much larger domestic incumbent with overlapping therapeutic categories.
  • BioMarin Pharmaceutical: BioMarin Pharmaceutical is a global rare disease specialist with established orphan drug commercialization capabilities, comparable in business model and regulatory pathway to Astrogen's Speragen program.
  • Jazz Pharmaceuticals: Jazz Pharmaceuticals is a specialty CNS pharmaceutical company with rare neurology assets, comparable as an established player that built commercial CNS franchises through licensing and acquisition.
  • Supernus Pharmaceuticals: Supernus Pharmaceuticals is a specialty CNS company focused on neurology and psychiatry products, comparable as a US-listed CNS-focused specialty pharma with established commercial infrastructure.

Regional players

  • Yuhan Corporation: Yuhan Corporation is one of Korea's largest pharmaceutical companies with CNS and rare disease programs, comparable as a domestic Korean pharmaceutical incumbent and potential commercial partner for Astrogen.

Others

  • IKTOS: IKTOS is a French AI-driven drug discovery company and Astrogen's technology partner for Parkinson's pipeline development, comparable as a collaborator/ecosystem participant rather than direct competitor.

Market position

Strengths5 records

Weaknesses6 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Astrogen, inc. social profiles

Digital presence

Astrogen, inc. compliance and trust

Trust signal

Compliance7 records

Astrogen, inc. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Astrogen, inc. leadership team

Management profile

Number of profiles

Profiles4 records

Astrogen, inc. funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Astrogen, inc. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Astrogen, inc.

What does Astrogen, inc. do?

Astrogen, Inc. is a clinical-stage pharmaceutical company developing small-molecule therapies for neurological and rare diseases. Its lead candidate Speragen (AST-001) is an oral syrup for autism spectrum disorder (ASD) targeting core social communication symptoms via SK channel regulation and dopamine signaling normalization. The pipeline also addresses Alzheimer's, Parkinson's, stroke, traumatic brain injury, and glioblastoma.

Is Astrogen, inc. a public or private company?

Astrogen, inc. is a private company. It is classified as venture growth investor backed and is currently operating.

When was Astrogen, inc. founded?

Astrogen, inc. was founded in 2017. It employs 1 to 10 people.

Where is Astrogen, inc. based?

Astrogen, inc. is headquartered in Daegu, South Korea, in the Asia region.

How does Astrogen, inc. make money?

Three revenue lines are on record. Product Supply Revenue is the primary driver. The others are technology Transfer and Licensing and royalty Income.

Who are Astrogen, inc.'s main competitors?

Direct peers on record are Curemark, Yamo Pharmaceuticals, PaxMedica and Marinus Pharmaceuticals. Broad incumbents are Hanmi Pharmaceutical, BioMarin Pharmaceutical, Jazz Pharmaceuticals and Supernus Pharmaceuticals. Yuhan Corporation is listed as a regional player. IKTOS is listed as an others.

Does Astrogen, inc. have an API?

No public API is recorded for Astrogen, inc..

What industry is Astrogen, inc. in?

Astrogen, inc.'s product category is CNS Pharmaceutical Development. Its primary akta.pro industry code is HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals